Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing

Leukemia

Volumn 25, Issue 9, 2011, Pages 1519-1522

  Greif, P A ^a,b   Yaghmaie, M ^a,b,c   Konstandin, N P ^a,b   Ksienzyk, B ^a,b   Alimoghaddam, K ^c   Ghavamzadeh, A ^c   Hauser, A ^b   Graf, A ^b   Krebs, S ^b   Blum, H ^b   Bohlander, S K ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TRANSCRIPTOME;

ARTICLE; CANCER PATIENT; CYTOGENETICS; DISEASE COURSE; EXOME; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SOMATIC MUTATION;

EID: 80052475500     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.114     Document Type: Article

References (15)

1. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558-561.
2. Zimonjic DB, Pollock JL, Westervel P, Popescu NC, Ley TJ. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci 2000; 97: 13306-13311.
3. Akagi T, Shih LY, Kato M, Kawamata N, Yamamoto G, Sanada M et al. Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 2009; 113: 1741-1748.
4. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8288. (Pubitemid 34651044)
5. Greif PA, Eck SH, Konstandin NP, Benet-Pages A, Ksienzyk B, Dufour A et al. Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia 2011; 25: 821-827.
6. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131-134. (Pubitemid 43033852)
7. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
8. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
9. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K et al. Wilms0 tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008; 26: 4595-4602.
10. Chan IT, Kutok JL, Williams IR, Cohen S, Moore S, Shigematsu H et al. Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood 2006; 108: 1708-1715. (Pubitemid 44316141)
11. Eklund EA. The role of HOX genes in malignant myeloid disease. Curr Opin Hematol 2007; 14: 85-89. (Pubitemid 46175091)
12. Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A et al. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 2007; 21: 403-410.
13. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008; 111: 4797-4808.
14. Chun EM, Park YJ, Kang HS, Cho HM, Jun DY, Kim YH. Expression of the apolipoprotein C-II gene during myelomonocytic differentiation of human leukemic cells. J Leukoc Biol 2001; 69: 645-650.
15. Weinberg JB, Volkheimer AD, Mihovilovic M, Jiang N, Chen Y, Bond K et al. Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia. Leukemia 2008; 22: 2184-2192.